Apatinib, a small-molecule TKI which selectively inhibits VEGFR-2 resulting in a decrease in endothelial proliferation, migration, and tumor microvascular density, is under evaluation in combination with pembrolizumab in a phase I/IIa trial (NCT03407976; APPEASE). The gene discussed is KDR; the disease is neoplasm.